University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations.
Each year, seasonal influenza causes serious illnesses in 3 million to 5 million people and 200,000 to 500,000 deaths. The 2009 H1N1 pandemic killed more than 14,000 people worldwide. Meanwhile, public health and bioterrorism concerns are heightened by new mutations of the H5N1 "bird flu" virus, published last week by the journal Nature, that could facilitate infection among mammals and humans.
Led by professor John Schrader, Canada Research Chair in Immunology and director of UBC's Biomedical Research Centre, the research team found that the 2009 H1N1 "swine flu" vaccine triggers antibodies that protect against many influenza viruses, including the lethal avian H5N1 "bird flu" strain.
Details are published today in the journal Frontiers in Immunology.
"The flu virus has a protein called hemagglutinin, or HA for short. This protein is like a flower with a head and a stem," says Schrader, a professor of medicine and pathology and laboratory medicine. "The flu virus binds to human cells via the head of the HA, much like a socket and plug. Current flu vaccines target the head of the HA to prevent infections, but because the flu virus mutates very quickly, this part of the HA changes rapidly, hence the need for different vaccines every flu season."
Vaccines contain bits of weak or dead germs that prompt the human immune system to produce antibodies that circulate in the blood to kill those specific germs. However, the research team found that the 2009 pandemic H1N1 vaccine induced broadly protective antibodies capable of fighting different variants of the flu virus.
"This is because, rather than attacking the variable head of the HA, the antibodies attacked the stem of the HA, neutralizing the flu virus," says Schrader. "The stem plays such an integral role in penetrating the cell that it cannot change between different variants of the flu virus."
The new discovery could pave the way to developing universal flu vaccines.
Schrader says the characteristics of the human immune system make it difficult for influenza vaccines to induce broadly protective antibodies against the HA stem. "The pandemic H1N1 swine flu was different, because humans had not been exposed to a similar virus," he adds.
Schrader has evidence that a vaccine based on a mixture of influenza viruses not circulating in humans but in animals should have the same effect and potentially make influenza pandemics and seasonal influenza a thing of the past.
The research team consists of scientists from UBC, the Universities of Ottawa and Toronto, the Ontario Agency for Health Protection and Promotion, the Canadian Food Inspection Agency and the BC Centre for Disease Control. The research was supported by grants from the Canadian Institutes for Health Research, the International Consortium for Anti-Virals and the Michael Smith Foundation for Health Research.
Â
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.